Adjuvant chemotherapy after pulmonary resection for lung cancer.

Date publication

août 2013

Journal

Thoracic surgery clinics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Mascaux C, Shepherd FA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23931022

Résumé

Adjuvant chemotherapy using a cisplatin-based regimen is currently recommended for patients with stage II and III non-small cell lung cancer (NSCLC) after complete tumor resection and may be considered for patients with stage IB NSCLC. Although adjuvant chemotherapy after complete resection of localized NSCLC is associated with an absolute survival advantage of approximately 5% at 5 years, there is still a relatively high risk of relapse even for early-stage NSCLC. Efforts are ongoing to identify new treatments in the adjuvant setting and to select patients for individualized treatment based on biomarkers.

Mots clés

Adjuvant, Biomarkers, Chemotherapy, Non–small cell lung cancer, Targeted therapy

Référence

Thorac Surg Clin. 2013 Aug;23(3):401-10